[Potential antiviral therapeutics for 2019 Novel Coronavirus]

Zhonghua Jie He He Hu Xi Za Zhi. 2020 Mar 12;43(3):170-172. doi: 10.3760/cma.j.issn.1001-0939.2020.03.004.
[Article in Chinese]


The recent outbreak of respiratory illness in Wuhan, China is caused by a novel coronavirus, named 2019-nCoV, which is genetically close to a bat-derived coronavirus. 2019-nCoV is categorized as beta genus coronavirus, same as the two other strains-severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV). Antiviral drugs commonly used in clinical practice, including neuraminidase inhibitors (oseltamivir, paramivir, zanamivir, etc.), ganciclovir, acyclovir and ribavirin, are invalid for 2019-nCoV and not recommended. Drugs are possibly effective for 2019-nCoV include: remdesivir, lopinavir/ritonavir, lopinavir/ritonavir combined with interferon-β, convalescent plasma, and monoclonal antibodies. But the efficacy and safety of these drugs for 2019-nCoV pneumonia patients need to be assessed by further clinical trials.


Keywords: 2019 novel coronavirus; Antiviral therapy; Infection.

MeSH terms

  • Antibodies, Monoclonal / therapeutic use
  • Antiviral Agents / therapeutic use*
  • Betacoronavirus / drug effects*
  • COVID-19
  • China
  • Coronavirus Infections / drug therapy*
  • Cytochrome P-450 CYP3A Inhibitors / therapeutic use
  • Humans
  • Interferon-beta
  • Lopinavir / therapeutic use
  • Middle East Respiratory Syndrome Coronavirus
  • Pneumonia, Viral / drug therapy*
  • Ritonavir / therapeutic use
  • SARS-CoV-2
  • Severe Acute Respiratory Syndrome / drug therapy


  • Antibodies, Monoclonal
  • Antiviral Agents
  • Cytochrome P-450 CYP3A Inhibitors
  • Lopinavir
  • Interferon-beta
  • Ritonavir

Supplementary concepts

  • COVID-19 drug treatment